P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 6, 2012, Pages 722-738

  Weisman, Gary A ^a,b   Woods, Lucas T ^a,b   Erb, Laurie ^a,b   Seye, Cheikh I ^c  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neuroinflammation; P2Y receptor; P2Y receptor agonist; P2Y receptor antagonist

Indexed keywords

BRILLINTA; CLOPIDOGREL; CYCLIC AMP; DENUFOSOL; DIQUAFOSOL; G PROTEIN COUPLED RECEPTOR; INS 45973; INS 48823; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; MRS 2690; MRS 2693; NUCLEOTIDASE; PRASUGREL; PROTEIN KINASE C; PSB 0474; PSB 1114; PSB 716; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y RECEPTOR AGONIST; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y13 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; PURINERGIC PY14 RECEPTOR; SURAMIN; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; DRY EYE; HUMAN; NERVOUS SYSTEM INJURY; NEUROPROTECTION; NONHUMAN; REVIEW; TISSUE REACTION;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; HUMANS; INFLAMMATION; NEURODEGENERATIVE DISEASES; PURINERGIC P2Y RECEPTOR AGONISTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y;

EID: 84869019324     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712803581047     Document Type: Review

References (255)

1. Burnstock, G.; Knight, G.E. Cellular distribution and functions of P2 receptor subtypes in different systems. Int. Rev. Cytol., 2004, 240, 31-304.
2. Sak, K.; Webb, T.E. A retrospective of recombinant P2Y receptor subtypes and their pharmacology. Arch. Biochem. Biophys., 2002, 397(1), 131-136.
3. Abbracchio, M.P.; Burnstock, G.; Boeynaems, J.M.; Barnard, E.A.; Boyer, J.L.; Kennedy, C.; Knight, G.E.; Fumagalli, M.; Gachet, C.; Jacobson, K.A.; Weisman, G.A. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev., 2006, 58(3), 281-341.
4. Bodin, P.; Burnstock, G. Purinergic signalling: ATP release. Neurochem. Res., 2001, 26(8-9), 959-969.
5. Fields, R.D. Nonsynaptic and nonvesicular ATP release from neurons and relevance to neuron-glia signaling. Semin. Cell. Dev. Biol., 2011, 22(2), 214-219.
6. Chekeni, F.B.; Elliott, M.R.; Sandilos, J.K.; Walk, S.F.; Kinchen, J.M.; Lazarowski, E.R.; Armstrong, A.J.; Penuela, S.; Laird, D.W.; Salvesen, G.S.; Isakson, B.E.; Bayliss, D.A.; Ravichandran, K.S. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature, 2010, 467(7317), 863-867.
7. Bao, L.; Locovei, S.; Dahl, G. Pannexin membrane channels are mechanosensitive conduits for ATP. FEBS Lett., 2004, 572(1-3), 65-68.
8. Seror, C.; Melki, M.T.; Subra, F.; Raza, S.Q.; Bras, M.; Saidi, H.; Nardacci, R.; Voisin, L.; Paoletti, A.; Law, F.; Martins, I.; Amendola, A.; Abdul-Sater, A.A.; Ciccosanti, F.; Delelis, O.; Niedergang, F.; Thierry, S.; Said-Sadier, N.; Lamaze, C.; Metivier, D.; Estaquier, J.; Fimia, G.M.; Falasca, L.; Casetti, R.; Modjtahedi, N.; Kanellopoulos, J.; Mouscadet, J.F.; Ojcius, D.M.; Piacentini, M.; Gougeon, M.L.; Kroemer, G.; Perfettini, J.L. Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. J. Exp. Med., 2011, 208(9), 1823-1834.
9. Bargiotas, P.; Krenz, A.; Hormuzdi, S.G.; Ridder, D.A.; Herb, A.; Barakat, W.; Penuela, S.; von Engelhardt, J.; Monyer, H.; Schwaninger, M. Pannexins in ischemia-induced neurodegeneration. Proc. Natl. Acad. Sci. USA, 2011, 108(51), 20772-20777.
10. Burnstock, G.; Dumsday, B.; Smythe, A. Atropine resistant excitation of the urinary bladder: the possibility of transmission via nerves releasing a purine nucleotide. Br. J. Pharmacol., 1972, 44(3), 451-461.
11. Burnstock, G. Purinergic signalling: past, present and future. Braz. J. Med. Biol. Res., 2009, 42(1), 3-8.
12. Neary, J.T.; Zimmermann, H. Trophic functions of nucleotides in the central nervous system. Trends Neurosci., 2009, 32(4), 189-198.
13. Burnstock, G.; Verkhratsky, A. Long-term(trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death. Cell Death Dis., 2010, 1, e9.
14. Fumagalli, M.; Brambilla, R.; D'Ambrosi, N.; Volonté, C.; Matteoli, M.; Verderio, C.; Abbracchio, M.P. Nucleotide-mediated calcium signaling in rat cortical astrocytes: Role of P2X and P2Y receptors. Glia, 2003, 43(3), 218-303.
15. Kreda, S.M.; Seminario-Vidal, L.; Heusden, C.; Lazarowski, E.R. Thrombin-promoted release of UDP-glucose from human astrocytoma cells. Br. J. Pharmacol., 2008, 153(7), 1528-1537.
16. 2 receptor. J. Neurochem., 2009, 109(5), 1300-1310.
17. 13 receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death. Free Radic. Biol. Med., 2010, 49(3), 416-426.
18. Brandenburg, L.O.; Jansen, S.; Wruck, C.J.; Lucius, R.; Pufe, T. Antimicrobial peptide rCRAMP induced glial cell activation through P2Y receptor signalling pathways. Mol. Immunol., 2010, 47(10), 1905-1913.
19. Köles, L.; Leichsenring, A.; Rubini, P.; Illes, P. P2 receptor signaling in neurons and glial cells of the central nervous system. Adv. Pharmacol., 2011, 61, 441-493.
20. Rodrigues, R.J.; Almeida, T.; de Mendonca, A.; Cunha, R.A. Interaction between P2X and nicotinic acetylcholine receptors in glutamate nerve terminals of the rat hippocampus. J. Mol. Neurosci., 2006, 30(1-2), 173-176.
21. Rodrigues, R.J.; Almeida, T.; Richardson, P.J.; Oliveira, C.R.; Cunha, R.A. Dual presynaptic control by ATP of glutamate release via facilitatory P2X1, P2X2/3, and P2X3 and inhibitory P2Y1, P2Y2, and/or P2Y4 receptors in the rat hippocampus. J. Neurosci., 2005, 25(27), 6286-6295.
22. Sperlagh, B.; Illes, P. Purinergic modulation of microglial cell activation. Purinergic Signal., 2007, 3(1-2), 117-127.
23. Fischer, W.; Krügel, U. P2Y receptors: focus on structural, pharmacological and functional aspects in the brain. Curr. Med. Chem., 2007, 14(23), 2429-2455.
24. 2 receptor activation. J. Neurochem., 2012.
25. 1 receptor is involved in the regulation of cytokine/chemokine transcription and cerebral damage in a rat model of cerebral ischemia. J. Cereb. Blood Flow Metab., 2011, 31(9), 1930-1941.
26. Nguyen, T.; Erb, L.; Weisman, G.A.; Marchese, A.; Heng, H.H.; Garrad, R.C.; George, S.R.; Turner, J.T.; O'Dowd, B.F. Cloning, expression, and chromosomal localization of the human uridine nucleotide receptor gene. J. Biol. Chem., 1995, 270(52), 30845-30848.
27. 2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. J. Biol. Chem., 1995, 270(9), 4185-4188.
28. Brinson, A.E.; Harden, T.K. Differential regulation of the uridine nucleotide-activated P2Y4 and P2Y6 receptors. SER-333 and SER-334 in the carboxyl terminus are involved in agonist-dependent phosphorylation desensitization and internalization of the P2Y4 receptor. J. Biol. Chem., 2001, 276(15), 11939-11948.
29. 2 nucleotide receptor. Mol. Cell. Biochem., 2005, 280(1-2), 35-45.
30. Shaver, S.R. P2Y receptors: biological advances and therapeutic opportunities. Curr. Opin. Drug Discov. Devel., 2001, 4(5), 665-670.
31. Jiang, Q.; Guo, D.; Lee, B.X.; Van Rhee, A.M.; Kim, Y.C.; Nicholas, R.A.; Schachter, J.B.; Harden, T.K.; Jacobson, K.A. A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. Mol. Pharmacol., 1997, 52(3), 499-507.
32. Jacobson, K.A.; Hoffmann, C.; Kim, Y.C.; Camaioni, E.; Nandanan, E.; Jang, S.Y.; Guo, D.P.; Ji, X.D.; von Kugelgen, I.; Moro, S.; Ziganshin, A.U.; Rychkov, A.; King, B.F.; Brown, S.G.; Wildman, S.S.; Burnstock, G.; Boyer, J.L.; Mohanram, A.; Harden, T.K. Molecular recognition in P2 receptors: ligand development aided by molecular modeling and mutagenesis. Prog. Brain Res., 1999, 120, 119-132.
33. Ivanov, A.A.; Costanzi, S.; Jacobson, K.A. Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling. J. Comput. Aided. Mol. Des., 2006, 20(7-8), 417-426.
34. Costanzi, S.; Mamedova, L.; Gao, Z.G.; Jacobson, K.A. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J. Med. Chem., 2004, 47(22), 5393-5404.
35. 2 receptor interactions in neuroinflammation. Mol. Neurobiol., 2012, in press.
36. Erb, L.; Liao, Z.; Seye, C.I.; Weisman, G.A. P2 receptors: intracellular signaling. Pflugers Arch., 2006, 452(5), 552-562.
37. Shenoy, S.K.; Lefkowitz, R.J. [-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci., 2011, 32(9), 521-533.
38. Hoffmann, C.; Ziegler, N.; Reiner, S.; Krasel, C.; Lohse, M.J. Agonist-selective, receptor-specific interaction of human P2Y receptors with beta-arrestin-1 and-2. J. Biol. Chem., 2008, 283(45), 30933-30941.
39. Palmer, R.K.; Boyer, J.L.; Schachter, J.B.; Nicholas, R.A.; Harden, T.K. Agonist action of adenosine triphosphates at the human P2Y1 receptor. Mol. Pharmacol., 1998, 54(6), 1118-1123.
40. Waldo, G.L.; Harden, T.K. Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor. Mol. Pharmacol., 2004, 65(2), 426-436.
41. Jacobson, K.A.; Boeynaems, J.M. P2Y nucleotide receptors: promise of therapeutic applications. Drug Discov. Today, 2010, 15(13-14), 570-578.
42. 1 receptor agonists. J. Med. Chem., 2002, 45(10), 2090-2100.
43. 1 receptor agonists. J. Med. Chem., 2002, 45(24), 5384-5396.
44. 1 receptor agonists. Eur. J. Med. Chem., 2009, 44(4), 1525-1536.
45. Nahum, V.; Tulapurkar, M.; Lévesque, S.A.; Sévigny, J.; Reiser, G.; Fischer, B. Diadenosine and diuridine poly(borano)phosphate analogues: synthesis, chemical and enzymatic stability, and activity at P2Y1 and P2Y2 receptors. J. Med. Chem., 2006, 49(6), 1980-1990.
46. Yelovitch, S.; Camden, J.; Weisman, G.A.; Fischer, B. Boranophosphate isoster controls P2Y-receptor subtype selectivity and metabolic stability of dinucleoside polyphosphate analogues. J. Med. Chem., 2012, 55(1), 437-448.
47. Eliahu, S.; Barr, H.M.; Camden, J.; Weisman, G.A.; Fischer, B. A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold. J. Med. Chem., 2010, 53(6), 2472-2481.
48. Eliahu, S.; Martín-Gil, A.; Perez de Lara, M.J.; Pintor, J.; Camden, J.; Weisman, G.A.; Lecka, J.; Sévigny, J.; Fischer, B. 2-MeSbeta, gamma-CCl2-ATP is a potent agent for reducing intraocular pressure. J. Med. Chem., 2010, 53(8), 3305-3319.
49. Léon, C.; Hechler, B.; Vial, C.; Leray, C.; Cazenave, J.P.; Gachet, C. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett., 1997, 403(1), 26-30.
50. Lambrecht, G.; Braun, K.; Damer, M.; Ganso, M.; Hildebrandt, C.; Ullmann, H.; Kassack, M.U.; Nickel, P. Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists. Curr. Pharm. Des., 2002, 8(26), 2371-2399.
51. Boyer, J.L.; Romero-Avila, T.; Schachter, J.B.; Harden, T.K. Identification of competitive antagonists of the P2Y1 receptor. Mol. Pharmacol., 1996, 50(5), 1323-1329.
52. Hechler, B.; Eckly, A.; Ohlmann, P.; Cazenave, J.P.; Gachet, C. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br. J. Haematol., 1998, 103(3), 858-866.
53. Boyer, J.L.; Mohanram, A.; Camaioni, E.; Jacobson, K.A.; Harden, T.K. Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. Br. J. Pharmacol., 1998, 124(1), 1-3.
54. Baurand, A.; Raboisson, P.; Freund, M.; Léon, C.; Cazenave, J.P.; Bourguignon, J.J.; Gachet, C. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur. J. Pharmacol., 2001, 412(3), 213-221.
55. Kim, H.S.; Ohno, M.; Xu, B.; Kim, H.O.; Choi, Y.; Ji, X.D.; Maddileti, S.; Marquez, V.E.; Harden, T.K.; Jacobson, K.A. 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J. Med. Chem., 2003, 46(23), 4974-4987.
56. Hechler, B.; Nonne, C.; Roh, E.J.; Cattaneo, M.; Cazenave, J.P.; Lanza, F.; Jacobson, K.A.; Gachet, C. MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J. Pharmacol. Exp. Ther., 2006, 316(2), 556-563.
57. 1 receptor antagonist. Br. J. Pharmacol., 2002, 135(8), 2004-2010.
58. 1 receptors. J. Med. Chem., 1998, 41(2), 183-190.
59. 35S]dATP alpha S binding sites in the adult rat neuraxis. Neuropharmacology, 1997, 36(9), 1243-1251.
60. 1 purinergic receptor in the human brain: striking neuronal localisation. J. Comp. Neurol., 2000, 421(3), 374-384.
61. 1 purinergic receptor in neurons and glial cells of the central nervous system. Brain Res. Mol. Brain Res., 2000, 78(1-2), 50-58.
62. Fujita, T.; Tozaki-Saitoh, H.; Inoue, K. P2Y1 receptor signaling enhances neuroprotection by astrocytes against oxidative stress via IL-6 release in hippocampal cultures. Glia, 2009, 57(3), 244-257.
63. Mishra, S.K.; Braun, N.; Shukla, V.; Füllgrabe, M.; Schomerus, C.; Korf, H.W.; Gachet, C.; Ikehara, Y.; Sévigny, J.; Robson, S.C.; Zimmermann, H. Extracellular nucleotide signaling in adult neural stem cells: synergism with growth factor-mediated cellular proliferation. Development, 2006, 133(4), 675-684.
64. Gerevich, Z.; Müller, C.; Illes, P. Metabotropic P2Y1 receptors inhibit P2X3 receptor-channels in rat dorsal root ganglion neurons. Eur. J. Pharmacol., 2005, 521(1-3), 34-38.
65. Ruan, H.Z.; Burnstock, G. Localisation of P2Y1 and P2Y4 receptors in dorsal root, nodose and trigeminal ganglia of the rat. Histochem. Cell Biol., 2003, 120(5), 415-426.
66. Bianco, F.; Fumagalli, M.; Pravettoni, E.; D'Ambrosi, N.; Volonte, C.; Matteoli, M.; Abbracchio, M.P.; Verderio, C. Pathophysiological roles of extracellular nucleotides in glial cells: differential expression of purinergic receptors in resting and activated microglia. Brain Res. Brain Res. Rev., 2005, 48(2), 144-156.
67. 2+ and calcitonin gene-related peptide release through metabotropic P2Y receptors in rat dorsal root ganglion neurons. Neuroscience, 2002, 111(2), 413-422.
68. Kobayashi, K.; Fukuoka, T.; Yamanaka, H.; Iyamanaka, H.; Dai, Y.; Obata, K.; Tokunaga, A.; Noguchi, K. Neurons and glial cells differentially express P2Y receptor mRNAs in the rat dorsal root ganglion and spinal cord. J. Comp. Neurol., 2006, 498(4), 443-454.
69. Gallego, D.; Gil, V.; Martinez-Cutillas, M.; Mañe, N.; Martin, M.T.; Jimenez, M. Purinergic neuromuscular transmission is absent in the colon of P2Y1 knocked out mice. J. Physiol., 2012.
70. Moore, D.; Iritani, S.; Chambers, J.; Emson, P. Immunohistochemical localization of the P2Y1 purinergic receptor in Alzheimer's disease. Neuroreport, 2000, 11(17), 3799-3803.
71. Soulet, C.; Hechler, B.; Gratacap, M.P.; Plantavid, M.; Offermanns, S.; Gachet, C.; Payrastre, B. A differential role of the platelet ADP receptors P2Y1 and P2Y12 in Rac activation. J. Thromb. Haemost., 2005, 3(10), 2296-2306.
72. del Puerto, A.; Díaz-Hernández, J.I.; Tapia, M.; Gomez-Villafuertes, R.; Benitez, M.J.; Zhang, J.; Miras-Portugal, M.T.; Wandosell, F.; Díaz-Hernández, M.; Garrido, J.J. Adenylate cyclase 5 coordinates the action of ADP, P2Y1, P2Y13 and ATPgated P2X7 receptors on axonal elongation. J. Cell Sci., 2012, 125(Pt 1), 176-188.
73. Tominaga, M.; Wada, M.; Masu, M. Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc. Natl. Acad. Sci. USA, 2001, 98(12), 6951-6956.
74. Chen, J.; Wang, L.; Zhang, Y.; Yang, J. P2Y1 purinoceptor inhibition reduces extracellular signal-regulated protein kinase 1/2 phosphorylation in spinal cord and dorsal root ganglia: implications for cancer-induced bone pain. Acta Biochim. Biophys. Sin(Shanghai), 2012, 44(4), 367-372.
75. Kittner, H.; Franke, H.; Fischer, W.; Schultheis, N.; Krügel, U.; Illes, P. Stimulation of P2Y1 receptors causes anxiolytic-like effects in the rat elevated plus-maze: implications for the involvement of P2Y1 receptor-mediated nitric oxide production. Neuropsychopharmacology, 2003, 28(3), 435-444.
76. Lustig, K.D.; Sportiello, M.G.; Erb, L.; Weisman, G.A. A nucleotide receptor in vascular endothelial cells is specifically activated by the fully ionized forms of ATP and UTP. Biochem. J., 1992, 284(Pt. 3), 733-739.
77. 2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc. Natl. Acad. Sci. USA, 1994, 91(8), 3275-3279.
78. 2U-purinoceptors. Br. J. Pharmacol., 1996, 117(1), 203-209.
79. 2 nucleotide receptor function: implications for proliferative and inflammatory pathways in astrocytes. Mol. Neurobiol., 2005, 31(1-3), 169-183.
80. 2Upurinoceptor: potent activation by diadenosine tetraphosphate. Br. J. Pharmacol., 1995, 116(1), 1619-1627.
81. Pendergast, W.; Yerxa, B.R.; Douglass, J.G.; Shaver, S.R.; Dougherty, R.W.; Redick, C.C.; Sims, I.F.; Rideout, J.L. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates. Bioorg. Med. Chem. Lett., 2001, 11(2), 157-160.
82. + excretion. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2011, 301(2), R510-R518.
83. 2 receptor agonist for the treatment of cystic fibrosis. J. Pharmacol. Exp. Ther., 2002, 302(3), 871-880.
84. Kellerman, D.; Evans, R.; Mathews, D.; Shaffer, C. Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease. Adv. Drug Deliv. Rev., 2002, 54(11), 1463-1474.
85. 2 agonist in healthy subjects. J. Ocul. Pharmacol. Ther., 2001, 17(2), 173-179.
86. Tauber, J.; Davitt, W.F.; Bokosky, J.E.; Nichols, K.K.; Yerxa, B.R.; Schaberg, A.E.; LaVange, L.M.; Mills-Wilson, M.C.; Kellerman, D.J. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium(INS365) ophthalmic solution for the treatment of dry eye. Cornea, 2004, 23(8), 784-792.
87. Deterding, R.R.; Lavange, L.M.; Engels, J.M.; Mathews, D.W.; Coquillette, S.J.; Brody, A.S.; Millard, S.P.; Ramsey, B.W. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am. J. Respir. Crit. Care Med., 2007, 176(4), 362-369.
88. Accurso, F.J.; Moss, R.B.; Wilmott, R.W.; Anbar, R.D.; Schaberg, A.E.; Durham, T.A.; Ramsey, B.W. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am. J. Respir. Crit. Care Med., 2011, 183(5), 627-634.
89. Jacobson, K.A.; Costanzi, S.; Ivanov, A.A.; Tchilibon, S.; Besada, P.; Gao, Z.G.; Maddileti, S.; Harden, T.K. Structure activity and molecular modeling analyses of ribose-and base-modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptors. Biochem. Pharmacol., 2006, 71(4), 540-549.
90. El-Tayeb, A.; Qi, A.; Muller, C.E. Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J. Med. Chem., 2006, 49(24), 7076-7087.
91. Ko, H.; Carter, R.L.; Cosyn, L.; Petrelli, R.; de Castro, S.; Besada, P.; Zhou, Y.; Cappellacci, L.; Franchetti, P.; Grifantini, M.; Van Calenbergh, S.; Harden, T.K.; Jacobson, K.A. Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg. Med. Chem., 2008, 16(12), 6319-6332.
92. El-Tayeb, A.; Qi, A.; Nicholas, R.A.; Müller, C.E. Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors. J. Med. Chem., 2011, 54(8), 2878-2890.
93. o and induce cell migration. J. Biol. Chem., 2005, 280(47), 39050-39057.
94. 12. J. Cell Sci., 2007, 120(Pt 9), 1654-1662.
95. o-mediated signal transduction. J. Cell Biol., 2001, 153(3), 491-501.
96. Murthy, K.S.; Makhlouf, G.M. Coexpression of ligand-gated P2X and G protein-coupled P2Y receptors in smooth muscle. Preferential activation of P2Y receptors coupled to phospholipase C(PLC)-beta1 via Galphaq/11 and to PLC-beta3 via Gbetagammai3. J. Biol. Chem., 1998, 273(8), 4695-4704.
97. Baltensperger, K.; Porzig, H. The P2U purinoceptor obligatorily engages the heterotrimeric G protein G16 to mobilize intracellular Ca2+ in human erythroleukemia cells. J. Biol. Chem., 1997, 272(15), 10151-10159.
98. Gallagher, C.J.; Salter, M.W. Differential properties of astrocyte calcium waves mediated by P2Y1 and P2Y2 receptors. J. Neurosci., 2003, 23(17), 6728-6739.
99. 2U-purinoceptors. Br. J. Pharmacol., 1996, 118(3), 704-710.
100. Weyler, S.; Baqi, Y.; Hillmann, P.; Kaulich, M.; Hunder, A.M.; Müller, I.A.; Müller, C.E. Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotidederived P2Y2 receptor antagonists. Bioorg. Med. Chem. Lett., 2008, 18(1), 223-227.
101. 2 nucleotide receptor to filamin A regulates migration of vascular smooth muscle cells. Circ. Res., 2008, 102(5), 581-588.
102. Arthur, D.B.; Georgi, S.; Akassoglou, K.; Insel, P.A. Inhibition of apoptosis by P2Y2 receptor activation: novel pathways for neuronal survival. J. Neurosci., 2006, 26(14), 3798-3804.
103. Franke, H.; Illes, P. Involvement of P2 receptors in the growth and survival of neurons in the CNS. Pharmacol. Ther., 2006, 109(3), 297-324.
104. Inoue, K. Purinergic systems in microglia. Cell Mol. Life Sci., 2008, 65(19), 3074-3080.
105. 2 nucleotide receptor-mediated responses in brain cells. Mol. Neurobiol., 2010, 41(2-3), 356-366.
106. Chen, Y.; Yao, Y.; Sumi, Y.; Li, A.; To, U.K.; Elkhal, A.; Inoue, Y.; Woehrle, T.; Zhang, Q.; Hauser, C.; Junger, W.G. Purinergic signaling: a fundamental mechanism in neutrophil activation. Sci. Signal., 2010, 3(125), ra45.
107. 2 nucleotide receptor up-regulation in submandibular gland cells from the NOD. B10 mouse model of Sjogren's syndrome. Arch. Oral Biol., 2005, 50(6), 533-540.
108. 2 nucleotide receptor mRNA expression is an immediate early gene response in activated thymocytes. Proc. Natl. Acad. Sci. USA, 1997, 94(3), 831-836.
109. 2 nucleotide receptors mediate uridine 5'-triphosphate-induced intimal hyperplasia in collared rabbit carotid arteries. Circulation, 2002, 106(21), 2720-2726.
110. 2 receptor in coronary artery smooth muscle cells. Mol. Pharmacol., 2004, 66(5), 1265-1274.
111. 2 nucleotide receptors in rat salivary gland cells during short-term culture. Am. J. Physiol., 1997, 273(3 Pt 1), C1100-C1107.
112. Rodríguez-Zayas, A.E.; Torrado, A.I.; Miranda, J.D. P2Y2 receptor expression is altered in rats after spinal cord injury. Int. J. Dev. Neurosci., 2010, 28(6), 413-421.
113. Franke, H.; Krugel, U.; Grosche, J.; Heine, C.; Hartig, W.; Allgaier, C.; Illes, P. P2Y receptor expression on astrocytes in the nucleus accumbens of rats. Neuroscience, 2004, 127(2), 431-441.
114. Lee, Y.J.; Han, S.B.; Nam, S.Y.; Oh, K.W.; Hong, J.T. Inflammation and Alzheimer's disease. Arch. Pharm. Res., 2010, 33(10), 1539-1556.
115. Cacabelos, R.; Alvarez, X.A.; Fernandez-Novoa, L.; Franco, A.; Mangues, R.; Pellicer, A.; Nishimura, T. Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Methods Find. Exp. Clin. Pharmacol., 1994, 16(2), 141-151.
116. 2 receptor transcription is increased by NF-kappa B and stimulates cyclooxygenase-2 expression and PGE2 released by intestinal epithelial cells. J. Immunol., 2009, 183(7), 4521-4529.
117. Wullaert, A.; Bonnet, M.C.; Pasparakis, M. NF-kappaB in the regulation of epithelial homeostasis and inflammation. Cell Res., 2011, 21(1), 146-158.
118. Honda, S.; Sasaki, Y.; Ohsawa, K.; Imai, Y.; Nakamura, Y.; Inoue, K.; Kohsaka, S. Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. J. Neurosci., 2001, 21(6), 1975-1982.
119. v integrin mediates astrocyte migration. J. Neurochem., 2005, 95(3), 630-640.
120. Washburn, K.B.; Neary, J.T. P2 purinergic receptors signal to STAT3 in astrocytes: Difference in STAT3 responses to P2Y and P2X receptor activation. Neuroscience, 2006, 142(2), 411-423.
121. Xu, J.; Wang, F.; Van Keymeulen, A.; Herzmark, P.; Straight, A.; Kelly, K.; Takuwa, Y.; Sugimoto, N.; Mitchison, T.; Bourne, H.R. Divergent signals and cytoskeletal assemblies regulate selforganizing polarity in neutrophils. Cell, 2003, 114(2), 201-214.
122. Ridley, A.J. Rho GTPases and cell migration. J. Cell Sci., 2001, 114(Pt 15), 2713-2722.
123. 2 receptors by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that involves related adhesion focal tyrosine kinase and protein kinase C. J. Biol. Chem., 1998, 273(5), 2653-2660.
124. i elevation can substitute for receptor activation. J. Biol. Chem., 1998, 273(36), 23110-23117.
125. 2 nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2(KDR/Flk-1). J. Biol. Chem., 2004, 279(34), 35679-35686.
126. 2 nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor receptors. J. Biol. Chem., 2004, 279(9), 8212-8218.
127. 2 nucleotide receptor. Consequences of truncation of the C terminus. J. Biol. Chem., 1998, 273(45), 29437-29444.
128. Norambuena, A.; Palma, F.; Poblete, M.I.; Donoso, M.V.; Pardo, E.; González, A.; Huidobro-Toro, J.P. UTP controls cell surface distribution and vasomotor activity of the human P2Y2 receptor through an epidermal growth factor receptor-transregulated mechanism. J. Biol. Chem., 2010, 285(5), 2940-2950.
129. Pooler, A.M.; Guez, D.H.; Benedictus, R.; Wurtman, R.J. Uridine enhances neurite outgrowth in nerve growth factor-differentiated PC12 [corrected]. Neuroscience, 2005, 134(1), 207-214.
130. 2 nucleotide receptors enhance ee-secretase-dependent amyloid precursor protein processing. J. Biol. Chem., 2005, 280(19), 18696-18702.
131. Boucsein, C.; Zacharias, R.; Färber, K.; Pavlovic, S.; Hanisch, U.K.; Kettenmann, H. Purinergic receptors on microglial cells: functional expression in acute brain slices and modulation of microglial activation in vitro. Eur. J. Neurosci., 2003, 17(11), 2267-2276.
132. Lai, M.K.; Tan, M.G.; Kirvell, S.; Hobbs, C.; Lee, J.; Esiri, M.M.; Chen, C.P.; Francis, P.T. Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer's disease neuropathology. J. Neural Transm., 2008, 115(8), 1165-1172.
133. Halassa, M.M.; Fellin, T.; Haydon, P.G. Tripartite synapses: roles for astrocytic purines in the control of synaptic physiology and behavior. Neuropharmacology, 2009, 57(4), 343-346.
134. Chorna, N.E.; Santiago-Perez, L.I.; Erb, L.; Seye, C.I.; Neary, J.T.; Sun, G.Y.; Weisman, G.A.; Gonzalez, F.A. P2Y receptors activate neuroprotective mechanisms in astrocytic cells. J. Neurochem., 2004, 91(1), 119-132.
135. Chen, X.; Molliver, D.C.; Gebhart, G.F. The P2Y2 receptor sensitizes mouse bladder sensory neurons and facilitates purinergic currents. J. Neurosci., 2010, 30(6), 2365-2372.
136. Wang, H.; Wang, D.H.; Galligan, J.J. P2Y2 receptors mediate ATP-induced resensitization of TRPV1 expressed by kidney projecting sensory neurons. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2010, 298(6), R1634-R1641.
137. Culpan, D.; MacGowan, S.H.; Ford, J.M.; Nicoll, J.A.; Griffin, W.S.; Dewar, D.; Cairns, N.J.; Hughes, A.; Kehoe, P.G.; Wilcock, G.K. Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease. Neurosci. Lett., 2003, 350(1), 61-65.
138. Tarkowski, E.; Liljeroth, A.M.; Minthon, L.; Tarkowski, A.; Wallin, A.; Blennow, K. Cerebral pattern of pro-and antiinflammatory cytokines in dementias. Brain Res. Bull., 2003, 61(3), 255-260.
139. Zhong, Z.; Deane, R.; Ali, Z.; Parisi, M.; Shapovalov, Y.; O'Banion, M.K.; Stojanovic, K.; Sagare, A.; Boillee, S.; Cleveland, D.W.; Zlokovic, B.V. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci., 2008, 11(4), 420-422.
140. Bell, R.D.; Winkler, E.A.; Sagare, A.P.; Singh, I.; LaRue, B.; Deane, R.; Zlokovic, B.V. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron, 2010, 68(3), 409-427.
141. Zlokovic, B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron, 2008, 57(2), 178-201.
142. Winkler, E.A.; Bell, R.D.; Zlokovic, B.V. Central nervous system pericytes in health and disease. Nat. Neurosci., 2011, 14(11), 1398-1405.
143. Terada, H.; Kajiura, T.; Kyoi, K.; Utsumi, S.; Hori, H. Effects of ATP on cerebral circulation--morphological observation of cerebral circulation and cerebral vasculature. No. To. Shinkei, 1976, 28(2), 151-156.
144. Miyagi, Y.; Kobayashi, S.; Nishimura, J.; Fukui, M.; Kanaide, H. Dual regulation of cerebrovascular tone by UTP: P2U receptormediated contraction and endothelium-dependent relaxation. Br. J. Pharmacol., 1996, 118(4), 847-856.
145. Guns, P.J.; Van Assche, T.; Fransen, P.; Robaye, B.; Boeynaems, J.M.; Bult, H. Endothelium-dependent relaxation evoked by ATP and UTP in the aorta of P2Y2-deficient mice. Br. J. Pharmacol., 2006, 147(5), 569-574.
146. Kennedy, C.; Burnstock, G. ATP produces vasodilation via P1 purinoceptors and vasoconstriction via P2 purinoceptors in the isolated rabbit central ear artery. Blood Vessels, 1985, 22(3), 145-155.
147. Ralevic, V.; Burnstock, G. Relative contribution of P2U-and P2Ypurinoceptors to endothelium-dependent vasodilatation in the golden hamster isolated mesenteric arterial bed. Br. J. Pharmacol., 1996, 117(8), 1797-1802.
148. Ralevic, V.; Burnstock, G. Discrimination by PPADS between endothelial P2Y-and P2U-purinoceptors in the rat isolated mesenteric arterial bed. Br. J. Pharmacol., 1996, 118(2), 428-434.
149. Olesen, S.P.; Crone, C. Substances that rapidly augment ionic conductance of endothelium in cerebral venules. Acta Physiol. Scand., 1986, 127(2), 233-241.
150. i. Am. J. Physiol. Heart Circ. Physiol., 2000, 279(4), H1625-H1634.
151. Guns, P.J.; Korda, A.; Crauwels, H.M.; Van Assche, T.; Robaye, B.; Boeynaems, J.M.; Bult, H. Pharmacological characterization of nucleotide P2Y receptors on endothelial cells of the mouse aorta. Br. J. Pharmacol., 2005, 146(2), 288-295.
152. Wihlborg, A.K.; Malmsjo, M.; Eyjolfsson, A.; Gustafsson, R.; Jacobson, K.; Erlinge, D. Extracellular nucleotides induce vasodilatation in human arteries via prostaglandins, nitric oxide and endothelium-derived hyperpolarising factor. Br. J. Pharmacol., 2003, 138(8), 1451-1458.
153. Kunapuli, S.P.; Daniel, J.L. P2 receptor subtypes in the cardiovascular system. Biochem. J., 1998, 336(Pt. 3), 513-523.
154. Anderson, C.M.; Nedergaard, M. Astrocyte-mediated control of cerebral microcirculation. Trends Neurosci., 2003, 26(7), 340-344.
155. Simard, M.; Arcuino, G.; Takano, T.; Liu, Q.S.; Nedergaard, M. Signaling at the gliovascular interface. J. Neurosci., 2003, 23(27), 9254-9262.
156. Lewis, C.J.; Ennion, S.J.; Evans, R.J. P2 purinoceptor-mediated control of rat cerebral(pial) microvasculature; contribution of P2X and P2Y receptors. J. Physiol., 2000, 527(Pt. 2), 315-324.
157. Webb, T.E.; Henderson, D.J.; Roberts, J.A.; Barnard, E.A. Molecular cloning and characterization of the rat P2Y4 receptor. J. Neurochem., 1998, 71(4), 1348-1357.
158. Brunschweiger, A.; Muller, C.E. P2 receptors activated by uracil nucleotides--an update. Curr. Med. Chem., 2006, 13(3), 289-312.
159. Jacobson, K.A.; Ivanov, A.A.; de Castro, S.; Harden, T.K.; Ko, H. Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal., 2009, 5(1), 75-89.
160. Communi, D.; Motte, S.; Boeynaems, J.M.; Pirotton, S. Pharmacological characterization of the human P2Y4 receptor. Eur. J. Pharmacol., 1996, 317(2-3), 383-389.
161. Luykenaar, K.D.; El-Rahman, R.A.; Walsh, M.P.; Welsh, D.G. Rho-kinase-mediated suppression of KDR current in cerebral arteries requires an intact actin cytoskeleton. Am. J. Physiol. Heart Circ. Physiol., 2009, 296(4), H917-H926.
162. Herold, C.L.; Qi, A.D.; Harden, T.K.; Nicholas, R.A. Agonist versus antagonist action of ATP at the P2Y4 receptor is determined by the second extracellular loop. J. Biol. Chem., 2004, 279(12), 11456-11464.
163. Jacobson, K.A.; Jarvis, M.F.; Williams, M. Purine and pyrimidine(P2) receptors as drug targets. J. Med. Chem., 2002, 45(19), 4057-4093.
164. Moore, D.J.; Chambers, J.K.; Wahlin, J.P.; Tan, K.B.; Moore, G.B.; Jenkins, O.; Emson, P.C.; Murdock, P.R. Expression pattern of human P2Y receptor subtypes: a quantitative reverse transcription-polymerase chain reaction study. Biochim. Biophys. Acta, 2001, 1521(1-3), 107-119.
165. 2Y purinoceptor subtypes recruit different mek activators in astrocytes. Br. J. Pharmacol., 2000, 129(5), 927-936.
166. Zonta, M.; Angulo, M.C.; Gobbo, S.; Rosengarten, B.; Hossmann, K.A.; Pozzan, T.; Carmignoto, G. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat. Neurosci., 2003, 6(1), 43-50.
167. Communi, D.; Parmentier, M.; Boeynaems, J.M. Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem. Biophys. Res. Commun., 1996, 222(2), 303-308.
168. Besada, P.; Shin, D.H.; Costanzi, S.; Ko, H.; Mathé, C.; Gagneron, J.; Gosselin, G.; Maddileti, S.; Harden, T.K.; Jacobson, K.A. Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor. J. Med. Chem., 2006, 49(18), 5532-5543.
169. Mamedova, L.K.; Wang, R.; Besada, P.; Liang, B.T.; Jacobson, K.A. Attenuation of apoptosis in vitro and ischemia/reperfusion injury in vivo in mouse skeletal muscle by P2Y6 receptor activation. Pharmacol. Res., 2008, 58(3-4), 232-239.
170. - secretion in mouse trachea. Cell. Physiol. Biochem., 2005, 16(1-3), 99-108.
171. Korcok, J.; Raimundo, L.N.; Du, X.; Sims, S.M.; Dixon, S.J. P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. J. Biol. Chem., 2005, 280(17), 16909-16915.
172. Chang, K.; Hanaoka, K.; Kumada, M.; Takuwa, Y. Molecular cloning and functional analysis of a novel P2 nucleotide receptor. J. Biol. Chem., 1995, 270(44), 26152-26158.
173. + currents in rat sympathetic neurones. Br. J. Pharmacol., 1999, 126(4), 1009-1017.
174. Nishida, M.; Sato, Y.; Uemura, A.; Narita, Y.; Tozaki-Saitoh, H.; Nakaya, M.; Ide, T.; Suzuki, K.; Inoue, K.; Nagao, T.; Kurose, H. P2Y6 receptor-Galpha12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J., 2008, 27(23), 3104-3115.
175. Mamedova, L.K.; Joshi, B.V.; Gao, Z.G.; von Kügelgen, I.; Jacobson, K.A. Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem. Pharmacol., 2004, 67(9), 1763-1770.
176. Robaye, B.; Boeynaems, J.M.; Communi, D. Slow desensitization of the human P2Y6 receptor. Eur. J. Pharmacol., 1997, 329(2-3), 231-236.
177. Calvert, J.A.; Atterbury-Thomas, A.E.; Leon, C.; Forsythe, I.D.; Gachet, C.; Evans, R.J. Evidence for P2Y1, P2Y2, P2Y6 and atypical UTP-sensitive receptors coupled to rises in intracellular calcium in mouse cultured superior cervical ganglion neurons and glia. Br. J. Pharmacol., 2004, 143(5), 525-532.
178. Bennett, G.C.; Ford, A.P.; Smith, J.A.; Emmett, C.J.; Webb, T.E.; Boarder, M.R. P2Y receptor regulation of cultured rat cerebral cortical cells: calcium responses and mRNA expression in neurons and glia. Br. J. Pharmacol., 2003, 139(2), 279-288.
179. Koizumi, S.; Shigemoto-Mogami, Y.; Nasu-Tada, K.; Shinozaki, Y.; Ohsawa, K.; Tsuda, M.; Joshi, B.V.; Jacobson, K.A.; Kohsaka, S.; Inoue, K. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature, 2007, 446(7139), 1091-1095.
180. Liu, G.D.; Ding, J.Q.; Xiao, Q.; Chen, S.D. P2Y6 receptor and immunoinflammation. Neurosci. Bull., 2009, 25(3), 161-164.
181. D'Ambrosi, N.; Iafrate, M.; Saba, E.; Rosa, P.; Volonte, C. Comparative analysis of P2Y4 and P2Y6 receptor architecture in native and transfected neuronal systems. Biochim. Biophys. Acta, 2007, 1768(6), 1592-1599.
182. Communi, D.; Robaye, B.; Boeynaems, J.M. Pharmacological characterization of the human P2Y11 receptor. Br. J. Pharmacol., 1999, 128(6), 1199-1206.
183. 2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling. Mol. Pharmacol., 2003, 63(6), 1356-1363.
184. Ingall, A.H.; Dixon, J.; Bailey, A.; Coombs, M.E.; Cox, D.; McInally, J.I.; Hunt, S.F.; Kindon, N.D.; Teobald, B.J.; Willis, P.A.; Humphries, R.G.; Leff, P.; Clegg, J.A.; Smith, J.A.; Tomlinson, W. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J. Med. Chem., 1999, 42(2), 213-220.
185. Meis, S.; Hamacher, A.; Hongwiset, D.; Marzian, C.; Wiese, M.; Eckstein, N.; Royer, H.D.; Communi, D.; Boeynaems, J.M.; Hausmann, R.; Schmalzing, G.; Kassack, M.U. NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methylphenylene)-carbonylimino)-bis(1,3-xylene-alpha, alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J. Pharmacol. Exp. Ther., 2010, 332(1), 238-247.
186. Moreschi, I.; Bruzzone, S.; Bodrato, N.; Usai, C.; Guida, L.; Nicholas, R.A.; Kassack, M.U.; Zocchi, E.; De Flora, A. NAADP+ is an agonist of the human P2Y11 purinergic receptor. Cell. Calcium, 2008, 43(4), 344-355.
187. Moreschi, I.; Bruzzone, S.; Nicholas, R.A.; Fruscione, F.; Sturla, L.; Benvenuto, F.; Usai, C.; Meis, S.; Kassack, M.U.; Zocchi, E.; De Flora, A. Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes. J. Biol. Chem., 2006, 281(42), 31419-31429.
188. 11, a purinergic receptor acting via cAMP, mediates secretion by pancreatic duct epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2001, 280(5), G795-G804.
189. Kaufmann, A.; Musset, B.; Limberg, S.H.; Renigunta, V.; Sus, R.; Dalpke, A.H.; Heeg, K.M.; Robaye, B.; Hanley, P.J. "Host tissue damage" signal ATP promotes non-directional migration and negatively regulates toll-like receptor signaling in human monocytes. J. Biol. Chem., 2005, 280(37), 32459-32467.
190. Vaughan, K.R.; Stokes, L.; Prince, L.R.; Marriott, H.M.; Meis, S.; Kassack, M.U.; Bingle, C.D.; Sabroe, I.; Surprenant, A.; Whyte, M.K. Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y11 receptor. J. Immunol., 2007, 179(12), 8544-8553.
191. Ecke, D.; Hanck, T.; Tulapurkar, M.E.; Schafer, R.; Kassack, M.; Stricker, R.; Reiser, G. Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor. Biochem. J., 2008, 409(1), 107-116.
192. Swennen, E.L.; Bast, A.; Dagnelie, P.C. Purinergic receptors involved in the immunomodulatory effects of ATP in human blood. Biochem. Biophys. Res. Commun., 2006, 348(3), 1194-1199.
193. Ullmann, H.; Meis, S.; Hongwiset, D.; Marzian, C.; Wiese, M.; Nickel, P.; Communi, D.; Boeynaems, J.M.; Wolf, C.; Hausmann, R.; Schmalzing, G.; Kassack, M.U. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J. Med. Chem., 2005, 48(22), 7040-7048.
194. Volonté, C.; Amadio, S.; D'Ambrosi, N.; Colpi, M.; Burnstock, G. P2 receptor web: complexity and fine-tuning. Pharmacol. Ther., 2006, 112(1), 264-280.
195. Zhang, F.L.; Luo, L.; Gustafson, E.; Palmer, K.; Qiao, X.; Liu, Y.H.; Chen, G.; Pramanik, B.; Laz, T.M.; Palmer, K.; Bayne, M.; Monsma, F.J., Jr. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J. Biol. Chem., 2001, 276(11), 8608-8615.
196. Soulet, C.; Sauzeau, V.; Plantavid, M.; Herbert, J.M.; Pacaud, P.; Payrastre, B.; Savi, P. Gi-dependent and-independent mechanisms downstream of the P2Y12 ADP-receptor. J. Thromb. Haemost., 2004, 2(1), 135-146.
197. 12 receptor in C6 cells. FEBS J., 2006, 273(8), 1843-1854.
198. Ben Addi, A.; Cammarata, D.; Conley, P.B.; Boeynaems, J.M.; Robaye, B. Role of the P2Y12 receptor in the modulation of murine dendritic cell function by ADP. J. Immunol., 2010, 185(10), 5900-5906.
199. Bodor, E.T.; Waldo, G.L.; Hooks, S.B.; Corbitt, J.; Boyer, J.L.; Harden, T.K. Purification and functional reconstitution of the human P2Y12 receptor. Mol. Pharmacol., 2003, 64(5), 1210-1216.
200. Jantzen, H.M.; Gousset, L.; Bhaskar, V.; Vincent, D.; Tai, A.; Reynolds, E.E.; Conley, P.B. Evidence for two distinct G-proteincoupled ADP receptors mediating platelet activation. Thromb. Haemost., 1999, 81(1), 111-117.
201. Xu, B.; Stephens, A.; Kirschenheuter, G.; Greslin, A.F.; Cheng, X.; Sennelo, J.; Cattaneo, M.; Zighetti, M.L.; Chen, A.; Kim, S.A.; Kim, H.S.; Bischofberger, N.; Cook, G.; Jacobson, K.A. Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. J. Med. Chem., 2002, 45(26), 5694-5709.
202. Dorsam, R.T.; Kunapuli, S.P. Central role of the P2Y12 receptor in platelet activation. J. Clin. Invest., 2004, 113(3), 340-345.
203. 12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur. Heart J., 2009, 30(16), 1964-1977.
204. Savi, P.; Herbert, J.M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin. Thromb. Hemost., 2005, 31(2), 174-183.
205. Niitsu, Y.; Jakubowski, J.A.; Sugidachi, A.; Asai, F. Pharmacology of CS-747(prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin. Thromb. Hemost., 2005, 31(2), 184-194.
206. Thebault, J.J.; Blatrix, C.E.; Blanchard, J.F.; Panak, E.A. Effects of ticlopidine, a new platelet aggregation inhibitor in man. Clin. Pharmacol. Ther., 1975, 18(4), 485-490.
207. Hollopeter, G.; Jantzen, H.M.; Vincent, D.; Li, G.; England, L.; Ramakrishnan, V.; Yang, R.B.; Nurden, P.; Nurden, A.; Julius, D.; Conley, P.B. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature, 2001, 409(6817), 202-207.
208. Savi, P.; Zachayus, J.L.; Delesque-Touchard, N.; Labouret, C.; Hervé, C.; Uzabiaga, M.F.; Pereillo, J.M.; Culouscou, J.M.; Bono, F.; Ferrara, P.; Herbert, J.M. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc. Natl. Acad. Sci. USA, 2006, 103(29), 11069-11074.
209. Gachet, C. ADP receptors of platelets and their inhibition. Thromb. Haemost., 2001, 86(1), 222-232.
210. Gachet, C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol. Ther., 2005, 108(2), 180-192.
211. van Giezen, J.J.; Humphries, R.G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost., 2005, 31(2), 195-204.
212. Cannon, C.P.; Husted, S.; Harrington, R.A.; Scirica, B.M.; Emanuelsson, H.; Peters, G.; Storey, R.F.; Investigators, D.-. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol., 2007, 50(19), 1844-1851.
213. Oestreich, J.H. Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr. Opin. Investig. Drugs, 2010, 11(3), 340-348.
214. 12). Bioorg. Med. Chem. Lett., 2001, 11(14), 1805-1808.
215. 12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thromb. Haemost., 2007, 97(5), 847-855.
216. Andó, R.D.; Méhész, B.; Gyires, K.; Illes, P.; Sperlágh, B. A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. Br. J. Pharmacol., 2010, 159(5), 1106-1117.
217. Hoffmann, K.; Baqi, Y.; Morena, M.S.; Glänzel, M.; Müller, C.E.; von Kügelgen, I. Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. J. Pharmacol. Exp. Ther., 2009, 331(2), 648-655.
218. Kunapuli, S.P.; Ding, Z.; Dorsam, R.T.; Kim, S.; Murugappan, S.; Quinton, T.M. ADP receptors--targets for developing antithrombotic agents. Curr. Pharm. Des., 2003, 9(28), 2303-2316.
219. 13-like receptors. Purinergic Signal., 2005, 1(2), 153-159.
220. 12 in microglia in rat brain. Glia, 2003, 44(3), 242-250.
221. Amadio, S.; Tramini, G.; Martorana, A.; Viscomi, M.T.; Sancesario, G.; Bernardi, G.; Volonté, C. Oligodendrocytes express P2Y12 metabotropic receptor in adult rat brain. Neuroscience, 2006, 141(3), 1171-1180.
222. Haynes, S.E.; Hollopeter, G.; Yang, G.; Kurpius, D.; Dailey, M.E.; Gan, W.B.; Julius, D. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci., 2006, 9(12), 1512-1519.
223. Braganhol, E.; Morrone F.B.; Bernardi, A.; Huppes, D.; Meurer, L.; Edelweiss, M.I.; Lenz, G.; Wink, M.R.; Robson, S.C.; Battastini, A.M. Selective NTPDase2 expression modulates in vivo rat glioma growth. Cancer Sci., 2009, 100(8), 1434-1442.
224. 13: identification and characterization of a novel Galphai-coupled ADP receptor from human and mouse. J. Pharmacol. Exp. Therap., 2002, 301(2), 705-713.
225. Burnstock, G. Historical review: ATP as a neurotransmitter. Trends Pharmacol. Sci., 2006, 27(3), 166-176.
226. Carrasquero, L.M.; Delicado, E.G.; Bustillo, D.; Gutiérrez-Martín, Y.; Artalejo, A.R.; Miras-Portugal, M.T. P2X7 and P2Y13 purinergic receptors mediate intracellular calcium responses to BzATP in rat cerebellar astrocytes. J. Neurochem., 2009, 110(3), 879-889.
227. Marteau, F.; Le Poul, E.; Communi, D.; Labouret, C.; Savi, P.; Boeynaems, J.M.; Gonzalez, N.S. Pharmacological characterization of the human P2Y13 receptor. Mol. Pharmacol., 2003, 64(1), 104-112.
228. Malaval, C.; Laffargue, M.; Barbaras, R.; Rolland, C.; Peres, C.; Champagne, E.; Perret, B.; Terce, F.; Collet, X.; Martinez, L.O. RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes. Cell Signal., 2009, 21(1), 120-127.
229. 13 receptor of ADP. Mol. Endocrinol., 2012, 26(1), 142-152.
230. Kim, Y.C.; Lee, J.S.; Sak, K.; Marteau, F.; Mamedova, L.; Boeynaems, J.M.; Jacobson, K.A. Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem. Pharmacol., 2005, 70(2), 266-274.
231. Jiménez, E.; Zafra, F.; Pérez-Sen, R.; Delicado, E.G.; Miras-Portugal, M.T.; Aragón, C.; López-Corcuera, B. P2Y purinergic regulation of the glycine neurotransmitter transporters. J. Biol. Chem., 2011, 286(12), 10712-10724.
232. Ortega, F.; Pérez-Sen, R.; Miras-Portugal, M.T. Gi-coupled P2YADP receptor mediates GSK-3 phosphorylation and beta-catenin nuclear translocation in granule neurons. J. Neurochem., 2008, 104(1), 62-73.
233. Chambers, J.K.; Macdonald, L.E.; Sarau, H.M.; Ames, R.S.; Freeman, K.; Foley, J.J.; Zhu, Y.; McLaughlin, M.M.; Murdock, P.; McMillan, L.; Trill, J.; Swift, A.; Aiyar, N.; Taylor, P.; Vawter, L.; Naheed, S.; Szekeres, P.; Hervieu, G.; Scott, C.; Watson, J.M.; Murphy, A.J.; Duzic, E.; Klein, C.; Bergsma, D.J.; Wilson, S.; Livi, G.P. A G protein-coupled receptor for UDP-glucose. J. Biol. Chem., 2000, 275(15), 10767-10771.
234. Abbracchio, M.P.; Boeynaems, J.M.; Barnard, E.A.; Boyer, J.L.; Kennedy, C.; Miras-Portugal, M.T.; King, B.F.; Gachet, C.; Jacobson, K.A.; Weisman, G.A.; Burnstock, G. Characterization of the UDP-glucose receptor(re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol. Sci., 2003, 24(2), 52-55.
235. Gao, Z.G.; Ding, Y.; Jacobson, K.A. UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation. Biochem. Pharmacol., 2010, 79(6), 873-879.
236. Ko, H.; Fricks, I.; Ivanov, A.A.; Harden, T.K.; Jacobson, K.A. Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor. J. Med. Chem., 2007, 50(9), 2030-2039.
237. Moore, D.J.; Murdock, P.R.; Watson, J.M.; Faull, R.L.; Waldvogel, H.J.; Szekeres, P.G.; Wilson, S.; Freeman, K.B.; Emson, P.C. GPR105, a novel Gi/o-coupled UDP-glucose receptor expressed on brain glia and peripheral immune cells, is regulated by immunologic challenge: possible role in neuroimmune function. Brain Res. Mol. Brain Res., 2003, 118(1-2), 10-23.
238. Skelton, L.; Cooper, M.; Murphy, M.; Platt, A. Human immature monocyte-derived dendritic cells express the G protein-coupled receptor GPR105(KIAA0001, P2Y14) and increase intracellular calcium in response to its agonist, uridine diphosphoglucose. J. Immunol., 2003, 171(4), 1941-1949.
239. Arase, T.; Uchida, H.; Kajitani, T.; Ono, M.; Tamaki, K.; Oda, H.; Nishikawa, S.; Kagami, M.; Nagashima, T.; Masuda, H.; Asada, H.; Yoshimura, Y.; Maruyama, T. The UDP-glucose receptor P2RY14 triggers innate mucosal immunity in the female reproductive tract by inducing IL-8. J. Immunol., 2009, 182(11), 7074-7084.
240. Bassil, A.K.; Bourdu, S.; Townson, K.A.; Wheeldon, A.; Jarvie, E.M.; Zebda, N.; Abuin, A.; Grau, E.; Livi, G.P.; Punter, L.; Latcham, J.; Grimes, A.M.; Hurp, D.P.; Downham, K.M.; Sanger, G.J.; Winchester, W.J.; Morrison, A.D.; Moore, G.B. UDP-glucose modulates gastric function through P2Y14 receptor-dependent and-independent mechanisms. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296(4), G923-G930.
241. Abbott, N.J.; Patabendige, A.A.; Dolman, D.E.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis., 2010, 37(1), 13-25.
242. Mills, J.H.; Thompson, L.F.; Mueller, C.; Waickman, A.T.; Jalkanen, S.; Niemela, J.; Airas, L.; Bynoe, M.S. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA, 2008, 105(27), 9325-9330.
243. Carman, A.J.; Mills, J.H.; Krenz, A.; Kim, D.G.; Bynoe, M.S. Adenosine receptor signaling modulates permeability of the bloodbrain barrier. J. Neurosci., 2011, 31(37), 13272-13280.
244. 2 receptor regulates LPS-induced neutrophil transendothelial migration in vitro. Mol. Immunol., 2010, 47(5), 991-999.
245. 2 nucleotide receptor mediates UTP-induced vascular cell adhesion molecule-1 expression in coronary artery endothelial cells. J. Biol. Chem., 2003, 278(27), 24960-24965.
246. 11 receptor. Biochem. J., 2008, 409(1), 107-116.
247. Yoshioka, K.; Saitoh, O.; Nakata, H. Heteromeric association creates a P2Y-like adenosine receptor. Proc. Natl. Acad. Sci. USA, 2001, 98(13), 7617-7622.
248. 1 purine receptors in rat hippocampus. Eur. J. Neurosci., 2007, 26(4), 890-902.
249. 1 receptors in rat brains. FEBS Lett., 2002, 531(2), 299-303.
250. 1 purinergic receptor activation in human astroglial cells. J. Neurosci. Res., 2008, 86(13), 2857-2866.
251. 2 receptor mRNA in astrocytes cultured from rat brain. Int. J. Immunopathol. Pharmacol., 2007, 20(2), 301-316.
252. Bianco, F.; Pravettoni, E.; Colombo, A.; Schenk, U.; Möller, T.; Matteoli, M.; Verderio, C. Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J. Immunol., 2005, 174(11), 7268-7277.
253. Bours, M.J.; Dagnelie, P.C.; Giuliani, A.L.; Wesselius, A.; Di Virgilio, F. P2 receptors and extracellular ATP: a novel homeostatic pathway in inflammation. Front. Biosci. (Schol. Ed.), 2011, 3, 1443-1456.
254. Arthur, D.B.; Akassoglou, K.; Insel, P.A. P2Y2 receptor activates nerve growth factor/TrkA signaling to enhance neuronal differentiation. Proc. Natl. Acad. Sci. USA, 2005, 102(52), 19138-19143.
255. Parvathenani, L.K.; Tertyshnikova, S.; Greco, C.R.; Roberts, S.B.; Robertson, B.; Posmantur, R. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J. Biol. Chem., 2003, 278(15), 13309-13317.